JP5288395B2 - 動物モデルとその作製方法 - Google Patents
動物モデルとその作製方法 Download PDFInfo
- Publication number
- JP5288395B2 JP5288395B2 JP2007545171A JP2007545171A JP5288395B2 JP 5288395 B2 JP5288395 B2 JP 5288395B2 JP 2007545171 A JP2007545171 A JP 2007545171A JP 2007545171 A JP2007545171 A JP 2007545171A JP 5288395 B2 JP5288395 B2 JP 5288395B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- observation
- animal model
- marker
- transplanted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000010171 animal model Methods 0.000 title claims description 57
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims description 126
- 239000003550 marker Substances 0.000 claims description 77
- 238000002054 transplantation Methods 0.000 claims description 42
- 201000009273 Endometriosis Diseases 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 34
- 230000003902 lesion Effects 0.000 claims description 32
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 210000003734 kidney Anatomy 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- 230000002357 endometrial effect Effects 0.000 claims description 17
- 210000004696 endometrium Anatomy 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003270 steroid hormone Substances 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 229940000406 drug candidate Drugs 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 3
- 239000005556 hormone Substances 0.000 description 26
- 229940088597 hormone Drugs 0.000 description 26
- 238000011282 treatment Methods 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 11
- 238000004020 luminiscence type Methods 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 8
- 210000005168 endometrial cell Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 238000005415 bioluminescence Methods 0.000 description 6
- 230000029918 bioluminescence Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000027758 ovulation cycle Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 229940126585 therapeutic drug Drugs 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003388 anti-hormonal effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001703 glandular epithelial cell Anatomy 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000545067 Venus Species 0.000 description 2
- 239000013059 antihormonal agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 241000059559 Agriotes sordidus Species 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 206010060781 Haemorrhagic ovarian cyst Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007545171A JP5288395B2 (ja) | 2005-11-16 | 2006-09-29 | 動物モデルとその作製方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005332113 | 2005-11-16 | ||
| JP2005332113 | 2005-11-16 | ||
| JP2007545171A JP5288395B2 (ja) | 2005-11-16 | 2006-09-29 | 動物モデルとその作製方法 |
| PCT/JP2006/319415 WO2007058021A1 (fr) | 2005-11-16 | 2006-09-29 | Modele animal et procede de production de ce modele |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2007058021A1 JPWO2007058021A1 (ja) | 2009-04-30 |
| JP5288395B2 true JP5288395B2 (ja) | 2013-09-11 |
Family
ID=38048413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545171A Expired - Fee Related JP5288395B2 (ja) | 2005-11-16 | 2006-09-29 | 動物モデルとその作製方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP5288395B2 (fr) |
| WO (1) | WO2007058021A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014033626A (ja) * | 2012-08-08 | 2014-02-24 | Juntendo | ヒト癌上皮細胞の遠隔転移のモデルマウス作出方法 |
| JPWO2017141987A1 (ja) * | 2016-02-19 | 2018-12-06 | コニカミノルタ株式会社 | 実験動物検体を定量評価することを特徴とする、非臨床試験方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU735644B2 (en) * | 1997-03-26 | 2001-07-12 | Reprogen, Inc. | Endometriosis mouse model |
-
2006
- 2006-09-29 JP JP2007545171A patent/JP5288395B2/ja not_active Expired - Fee Related
- 2006-09-29 WO PCT/JP2006/319415 patent/WO2007058021A1/fr active Application Filing
Non-Patent Citations (5)
| Title |
|---|
| JPN6011062230; ＫＵＤＯＨ， Ｍ． ｅｔ ａｌ: 'Ｉｎｈｉｂｉｔｏｒｙ ｅｆｆｅｃｔｓ ｏｆ ａ ｎｏｖｅｌ ａｒｏｍａｔａｓｅ ｉｎｈｉｂｉｔｏｒ， ＹＭ５１１， ｏｎ ｇｒｏｗｔｈ ｏｆ ｅｎｄｏｍｅｔｒｉａｌ ｅｘｐｌａｎｔｓ ａｎｄ ｉｎｓｕ' Ｊ． Ｓｔｅｒｏｉｄ Ｂｉｏｃｈｅｍ． Ｍｏｌ． Ｂｉｏｌ． Ｖｏｌ． ６３， Ｎｏ． １-３, 1997, ｐ． ７５-８０ * |
| JPN6011062231; ＳＡＫＵＲＡ， Ｙ． ｅｔ ａｌ．: 'Ｈｉｓｔｏｌｏｇｉｃａｌ ｓｔｕｄｉｅｓ ｏｎ ｔｈｅ ｔｈｅｒａｐｅｕｔｉｃ ｅｆｆｅｃｔ ｏｆ ｓｕｓｔａｉｎｅｄ-ｒｅｌｅａｓｅ ｍｉｃｒｏｓｐｈｅｒｅｓ ｏｆ ａ ｐｏｔｅｎｔ ＬＨＲＨ ａｇ' Ｅｎｄｏｃｒｉｎｏｌｏｇｉａ Ｊａｐｏｎｉｃａ Ｖｏｌ． ３７， Ｎｏ． ５, 1990, ｐ． ７１９-７２９ * |
| JPN6011062232; ＪＥＮＫＩＮＳ， Ｄ． Ｅ． ｅｔ ａｌ: 'Ｂｉｏｌｕｍｉｎｅｓｃｅｎｔ ｉｍａｇｉｎｇ （ＢＬＩ） ｔｏ ｉｍｐｒｏｖｅ ａｎｄ ｒｅｆｉｎｅ ｔｒａｄｉｔｉｏｎａｌ ｍｕｒｉｎｅ ｍｏｄｅｌｓ ｏｆ ｔｕｍｏｒ ｇｒｏｗｔｈ ａｎｄ ｍｅｔ' Ｃｌｉｎｉｃａｌ ＆ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｍｅｔａｓｔａｓｉｓ Ｖｏｌ． ２０, 2003, ｐ． ７３３-７４４ * |
| JPN6011062234; Ｍｅｔａｂｏｌｉｓｍ ｏｆ ［３Ｈ］ｅｑｕｉｌｉｎ ｉｎ ｎｏｒｍａｌ ａｎｄ ｍａｌｉｇｎａｎｔ ｈｕｍａｎ ｅｎｄｏｍｅｔｒｉｕｍ ａｎｄ ｉｎ ｅｎｄｏｍｅｔｒｉａｌ ａｄｅｎｏｃａｒｃｉｎｏｍ: 'ＢＨＡＶＮＡＮＩ， Ｂ． Ｒ． ｅｔ ａｌ．' Ｊ． Ｓｔｅｒｏｉｄ Ｂｉｏｃｈｅｍ． Ｍｏｌｅｃ． Ｂｉｏｌ． Ｖｏｌ． ３８， Ｎｏ． ４, 1991, ｐ． ４３３-４３９ * |
| JPN6012056303; 升田博隆 他: '新しい子宮内膜症モデルマウスの作成' 日本不妊学会雑誌 第５０巻、第４号, 20051001, ｐ． ２３９， Ｐ-０６６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007058021A1 (fr) | 2007-05-24 |
| JPWO2007058021A1 (ja) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ji et al. | Multimodal imaging for DREADD-expressing neurons in living brain and their application to implantation of iPSC-derived neural progenitors | |
| ES2525669T3 (es) | Inhibidores de la vascularización | |
| Al Nakouzi et al. | The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer | |
| CN104507965B (zh) | 作为血清和组织生化标志物的bag3 | |
| Sigl-Glöckner et al. | Effects of sexual experience and puberty on mouse genital cortex revealed by chronic imaging | |
| De Vocht et al. | Labeling of Luciferase/eGFP-expressing bone marrow-derived stromal cells with fluorescent micron-sized iron oxide particles improves quantitative and qualitative multimodal imaging of cellular grafts in vivo | |
| JP5288395B2 (ja) | 動物モデルとその作製方法 | |
| CN109152799A (zh) | 胰腺干细胞及其用途 | |
| Suo et al. | Murine xenograft model for human uterine fibroids: an in vivo imaging approach | |
| Thorp et al. | CCR2+ monocytes promote white matter injury and cognitive dysfunction after myocardial infarction | |
| KR101790370B1 (ko) | 췌장 베타 세포에서 인슐린 분비를 향상시키기 위한 ｐ２ｘ 퓨린성 수용체 효능제의 용도 | |
| US20070025914A1 (en) | Bronchioalveolar stem cells and uses thereof | |
| Alderman et al. | Mouse paralaminar amygdala excitatory neurons migrate and mature during adolescence | |
| De Schaepdrijver et al. | Juvenile animal toxicity assessments: decision strategies and study design | |
| KR102125084B1 (ko) | 신규한 교모세포종 환자 유래 이종 이식 모델 및 이의 용도 | |
| US12083149B2 (en) | Amelioration and treatment of chronic lung disease using pluripotent stem cells | |
| US20180050068A1 (en) | Metastatic cancer decoy trap | |
| JP2008148693A (ja) | 幹細胞の単離方法 | |
| KR102420226B1 (ko) | Gaba 신호가 활성화된 피하지방조직 줄기세포를 포함하는 염증 및 대사질환 치료용 약학 조성물 | |
| JP6436669B2 (ja) | 子宮肉腫転移モデル動物 | |
| Wolffs et al. | Calcium-sensing receptor antagonism as a novel therapeutic for pulmonary fibrosis | |
| TWI690321B (zh) | 用於治療心肌肥厚之醫藥組合物 | |
| CN109744199A (zh) | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 | |
| Ratko et al. | Role of uroguanylin's signalling pathway in the development of ischaemic stroke | |
| He et al. | Ultrasound Molecular Imaging of Neovascularization for Evaluation of Endometrial Receptivity Using Magnetic iRGD-Modified Lipid-Polymer Hybrid Microbubbles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130408 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130430 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130529 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |